Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.ARMP · Entity 6329 | Director | March 09, 2026 | March 12, 2026 |
| BIOGEN INC.BIIB · Entity 1675 | Chief Financial Officer | February 13, 2026 | February 18, 2026 |
| HERTZ GLOBAL HOLDINGS, INCHTZ · Entity 5147 | Sr VP Chief Accounting Officer | April 29, 2018 | May 01, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date March 09, 2026 · Filed March 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2036-03-09 | Direct | 25,640 |
Reported balance
After 2026-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-09 · Grant · Acquired 25,640 · Balance 25,640 F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,450 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,450 · Balance 8,450 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
HERTZ GLOBAL HOLDINGS, INC
Report date April 29, 2018 · Filed May 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,062 |
Ending reported balance
After 2018-04-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-04-29 · Exercise / conversion · Acquired 798 · Balance 6,257 F1: Each Performance Stock Unit represents a contingent right to receive one share of HTZ common stock. The Performance Stock Units were initially granted in 2015 and the amount of Performance Stock Units eligible for vesting is subject to the satisfaction of performance goals for 2016 and 2017. These Performance Stock Units are eligible for vesting based on the satisfaction of the Customer Satisfaction metric, subject to continued employment on the applicable vesting date. Row 2 · 2018-04-29 · Tax withholding · Disposed 195 · Balance 6,062 F2: Shares withheld to pay tax liabilities incident to the vesting of Performance Stock Units. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-04-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-04-29 · Exercise / conversion · Disposed 798 · Balance 0 F1: Each Performance Stock Unit represents a contingent right to receive one share of HTZ common stock. The Performance Stock Units were initially granted in 2015 and the amount of Performance Stock Units eligible for vesting is subject to the satisfaction of performance goals for 2016 and 2017. These Performance Stock Units are eligible for vesting based on the satisfaction of the Customer Satisfaction metric, subject to continued employment on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Performance Stock Unit represents a contingent right to receive one share of HTZ common stock. The Performance Stock Units were initially granted in 2015 and the amount of Performance Stock Units eligible for vesting is subject to the satisfaction of performance goals for 2016 and 2017. These Performance Stock Units are eligible for vesting based on the satisfaction of the Customer Satisfaction metric, subject to continued employment on the applicable vesting date.
F2: Shares withheld to pay tax liabilities incident to the vesting of Performance Stock Units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2026 Filed Mar 12, 2026 01:18 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 25,640 | $0.00 Strike: $11.61 | $0.00 |
DisclosureSEC source: 0001104659-26-026589 · tm268588-5_4seq1.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,640 Underlying: Common Stock · 25,640 shares Expires 2036-03-09 F1 · derivative.exercise_date: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 01:14 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000032 · form4.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,450 Underlying: Common Stock · 8,450 shares Expires 2029-02-13 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 3,511 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · derivative · entry 9 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,024 Underlying: Common Stock · 3,511 shares Expires 2025-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · derivative · entry 8 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 704 Underlying: Common Stock · 703 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 789 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · derivative · entry 7 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 789 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 1,063 | $201.18 | $213,854.34 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · nonDerivative · entry 6 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,471.7483 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 3,511 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · nonDerivative · entry 5 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,534.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 207 | $201.18 | $41,644.26 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · nonDerivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,023.7483 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 703 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · nonDerivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,230.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 273 | $201.18 | $54,922.14 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,527.7483 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 789 | $0.00 | $0.00 |
DisclosureSEC source: 0000875045-26-000021 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,800.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:44 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 834 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004457 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 834 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:44 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 245 | $142.54 | $34,922.30 |
DisclosureSEC source: 0001127602-25-004457 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,011.7483 Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:44 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 834 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-004457 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,256.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003958 · form4.xml · derivative · entry 7 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,407 Underlying: Common Stock · 703 shares Expires 2027-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 788 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003958 · form4.xml · derivative · entry 6 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 789 Underlying: Common Stock · 788 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 244 | $141.35 | $34,489.40 |
DisclosureSEC source: 0001127602-25-003958 · form4.xml · nonDerivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,422.7483 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003958 · form4.xml · nonDerivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,666.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 232 | $141.35 | $32,793.20 |
DisclosureSEC source: 0001127602-25-003958 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,963.7483 Read SEC document |
| February 07, 2025 Filed Feb 10, 2025 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 788 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003958 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,195.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2025 Filed Feb 10, 2025 23:48 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,535 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-003958 · form4.xml · derivative · entry 5 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,535 Underlying: Common Stock · 10,535 shares Expires 2025-02-06 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:18 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001104659-25-010558 · tm255864-4_4seq1.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,343 Underlying: Common Stock · 54,343 shares Expires 2035-02-05 F1 · derivative.exercise_date: The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 351 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028860 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 351 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing on the first anniversary of the grant date of 12/8/2021. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 170 | $157.78 | $26,822.60 |
DisclosureSEC source: 0001127602-24-028860 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,407.7483 Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 351 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-028860 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,577.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:03 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 54,343 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035730 · tm249071-3_4seq1.xml · derivative · entry 2 Kramer Robin · CIK 0001609222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,009 Underlying: Common Stock · 54,343 shares Expires 2034-03-14 F2 · derivative.exercise_date: The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date. Read SEC document |
| March 14, 2024 Filed Mar 19, 2024 00:03 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 39,666 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001104659-24-035730 · tm249071-3_4seq1.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,666 Underlying: Common Stock · 39,666 shares Expires 2034-03-14 F1 · derivative.exercise_date: The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:31 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 537 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006215 · form4.xml · derivative · entry 7 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 537 shares Expires 2024-02-18 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 431 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006215 · form4.xml · derivative · entry 6 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 537 Underlying: Common Stock · 431 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionPerformance Stock Unit · Derivative | 914 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006215 · form4.xml · derivative · entry 5 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 914 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 127 | $219.08 | $27,823.16 |
DisclosureSEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,226.7483 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 431 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,353.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 269 | $219.08 | $58,932.52 |
DisclosureSEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,922.7483 Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 02:31 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 914 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,191.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 833 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004797 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 834 Underlying: Common Stock · 833 shares Expires 2025-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 245 | $240.98 | $59,040.10 |
DisclosureSEC source: 0001127602-24-004797 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,277.7483 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 23:01 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004797 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,522.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 788 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004306 · form4.xml · derivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,577 Underlying: Common Stock · 788 shares Expires 2026-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing one year after the grant date of 02/08/2023. Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 253 | $240.30 | $60,795.90 |
DisclosureSEC source: 0001127602-24-004306 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,689.7483 Read SEC document |
| February 08, 2024 Filed Feb 10, 2024 01:06 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 788 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004306 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,942.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 10, 2024 01:06 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 2,110 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-004306 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,110 Underlying: Common Stock · 2,110 shares Expires 2027-02-07 F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:33 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantPerformance Stock Unit · Derivative | 914 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002808 · form4.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 914 Underlying: Common Stock · 914 shares Expires 2024-02-18 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 18, 2021. The PSUs will vest on February 18, 2024. Read SEC document |
| December 21, 2023 Filed Dec 27, 2023 02:54 UTC | Armata Pharmaceuticals, Inc. ARMP · Entity 6329 | GrantStock Options (Right to Buy) · Derivative | 10,461 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001104659-23-129369 · tm2333426-6_4seq1.xml · derivative · entry 1 Kramer Robin · CIK 0001609222 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 Underlying: Common Stock · 10,461 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock option vests immediately prior to the Company's 2024 annual shareholders meeting. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 351 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029441 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351 Underlying: Common Stock · 351 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vest in three (3) equal annual installments commencing on the first anniversary of the grant date of 12/8/2021. Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 170 | $239.29 | $40,679.30 |
DisclosureSEC source: 0001127602-23-029441 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,154.7483 Read SEC document |
| December 08, 2023 Filed Dec 12, 2023 22:02 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 351 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-029441 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,324.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:35 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 252 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020236 · form4.xml · derivative · entry 3 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 252 shares Expires 2023-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units vested in three (3) equal annual installments commencing one year after the grant date of 07/01/2020. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:35 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 122 | $284.85 | $34,751.70 |
DisclosureSEC source: 0001127602-23-020236 · form4.xml · nonDerivative · entry 2 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,973.7483 Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:35 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 252 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-020236 · form4.xml · nonDerivative · entry 1 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,095.7483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 22:01 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 454 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006519 · form4.xml · derivative · entry 4 Kramer Robin · CIK 0001609222 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968 Underlying: Common Stock · 454 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.